Abstract: Sumoylation, an important posttranslational modification process, is involved in regulating bioactivities of diverse proteins. GATA4, a cardiac enriched dual zinc finger transcription factor, plays a critical role in regulating cardiac specified genes. Here, we demonstrated that GATA4 is sumoylated by SUMO-1, which resulted in enhanced GATA4 transcriptional activity. We further revealed that lysine 366 of GATA4 constituted a major sumyolation site. Conversion of lysine 366 to arginine 366 resulted in reduced GATA4 nuclear occupation, suggesting that SUMO modification may also modulate GATA4 nuclear localization. In GATA4 sumoylation, Pias1 served as an E3 ligase and positively modulated GATA4 transactivation via its RING finger domain. In the presence of SUMO-1 and/or PIAS1, GATA4 triggered the activation of cardiogenic genes in pluripotent 10T1/2 fibroblast. GATA4 was identified as a SUMO-1 targeted transcription factor and together with Pias1 was shown to be a potent regulator of cardiac gene activity.
Introduction
There is a growing trend that posttranslational modifications by small ubiquitin-like modifier (SUMO) are acting as important regulators of transcription factor activity (1) . SUMO modification is accomplished by the reversible attachment of SUMO family members to the acceptor lysine residue(s) located in the target proteins, with the help of activating enzyme SAE1/2 and conjugating enzyme Ubc9. The process of sumoylation is similar to ubiquitination, but instead of directing the target protein towards proteolysis, it alters functional activity of targets by regulating protein-protein interactions (2) , nucleo-cytoplasmic translocalization (3), protein-DNA binding activity (4) and/or protein stability (5, 6) .
For instance, SUMO modification inhibited Elk-1 activity via HDAC-2-mediated repression (7, 8) , whereas DNA binding activities of heat shock protein2 and P53
were increased through SUMO-1 modification (9,10).
Three SUMO members have been identified in higher vertebrates in which SUMO-1 is only 50% identical to the highly similar SUMO-2 and -3 (11) . In general, the most frequent lysine residue for sumoylation is localized in the SUMO-recognizable canonical sequence ψKXE (12) where ψ stands for a large hydrophobic amino acid and X represents any residue although the lysine residue harbored in ψKXG/D or in other non-consensus sequences may also be SUMO-targeted (13, 14) . A large number of proteins has been revealed to be the targets of SUMO (15) (16) (17) (18) (19) (20) (21) (22) (23) , pointing to the possibility that SUMO may play more important and extensive roles in modulating many cellular processes via SUMO modification of target proteins. SAE1/2 and Ubc9 were found to be sufficient to direct the SUMO ligation of some targets, while SUMO E3 ligase may also stimulate sumoylation efficiency and direct substrate specificity for SUMO modification (1, 24) . There are three different classes of SUMO E3 ligase represented by PIAS (protein inhibitors of activated STAT) family (25) , the nucleoporin RanBP2 (26) and by guest on July 17, 2017 http://www.jbc.org/ Downloaded from polycomb protein 2 (Pc2) (27) . Among these, only PIAS proteins are found to facilitate sumoylation via its RING finger domain that is similar to the one contained in the E3 ligase involved in ubiquitination. PIAS super family is composed of 5 members: PIAS1, PIAS3, PIASxa, PIASxb and PIASy, all of which have been proven to possess E3 ligase activity linked to their conserved RING finger domains (28) (29) (30) and may also influence the activity of targets via a sumoylation-independent mechanism (30) (31) (32) .
GATA4 is a transcription factor belonging to the GATA super family composed of six members with GATA1, 2 and 3 largely restricted to hematopoietic lineage and GATA4, 5 and 6 abundant in heart. This family of transcription factors is characterized by the existence of two centrally located zinc finger domains that recognize the consensus motif (A/T)GATA(A/G) found in regulatory region of the target genes such as α-MHC (33), ANF (34) . Gene targeting and null mutation studies have revealed that GATA4 plays a critical role in the regulation of embryogenesis as well as heart development. Mice with deletion of GATA4 locus exhibit embryonic lethality at E9.5 with a defect in fusion of two primordial tubes (35) , whereas selective overexpression of GATA4 in the heart results in cardiac hypertrophy (36) . Recent studies also show that GATA4 serves as a survival factor for the cardiomyocytes which protects the heart from doxorubicin-induced cardio toxicity (37) . The transcriptional function of GATA4 is modulated via protein-protein interaction and/or posttranslational modifications.
For instance, interaction of GATA4 with other GATA family member GATA6 cooperatively activates ANF and BNP promoter (38) , and phosphorylation on S105 in GATA4 by MAP kinase enhances its function of promoting cardiomyocytes differentiation as well as cardiomyocytes hypertrophy (39, 40) , suggesting that the posttranslational modification on GATA4 is critical for its functional performance in the cellular physiological as well as pathological processes.
by guest on July 17, 2017 http://www.jbc.org/ Downloaded from GATA2 was shown to be a substrate for SUMO1/2 and PIASy suppressed GATA2 activation capacity without significantly affecting its DNA binding ability (41) . More recently, GATA1 was also shown to be a SUMO-1 target and PIASy again specifically repressed the activation of GATA-dependent promoters (21) .
These studies lend support that SUMO modification may be implicated in modulating functional activity of other GATA family members. We initiated this study to determine if SUMO modification would alter GATA4 functional activity.
We found that GATA4 is indeed modified by SUMO-1 in both vivo and vitro with E3 ligase PIAS1 strongly enhancing the sumoylation efficiency. In striking contrast to studies of GATA1 and GATA2, SUMO modification resulted in enhanced GATA4 transcriptional activation and strongly induced the transcriptional activity of endogenous cardiac specific genes in pluripotent 10T1/2 fibroblast cells. Given that GATA4 plays a pivotal role in the heart development, this study provides novel insight into the potential role of the SUMO family in facilitating cardiac gene activity.
Materials and Methods
Expression vectors, reporter genes and siRNA. An atrial natriuretic factor gene promoter Luciferase report construct (ANF-Luc) was kindly provided by Dr. Mona Nemer. GST-Ubc9 and GST-SUMO-GG were gifts from Dr. Jorma J. Palvimo and GST-SAE1/2 from Dr. Ron T. Hay. Myc-tagged full length mouse GATA4 was described (42) . Mammalian expression plasmids for Flag-sumo-1, HA-PIAS1 and its Ring-domain mutants were described (24) . GATA4 point mutant was generated by PCR using oligonucleotide primer with a mutated site from lysine to arginine, on lysine 366. PCR generated DNA product was inserted into a pCDNA3.1-GATA4 expression vector by using restriction enzymes NotI and XbaI. The mutation was verified by sequencing. The sequence of this primer for point-targeted mutagenesis is available upon request. Ubc9 siRNA was detailed previously(3). Transdifferentiation assays. Pluripotent 10T1/2 fibroblasts were maintained at low density (<30%) in 10% fetal bovine serum (FBS) plus DMEM in 6 cm plates prior to transfection. Transfections were performed 24 h later with GATA4 and mutants in the presence or absence of SUMO-1/PIAS1 plasmid based expression vectors, Media was replaced with DMEM plus 2% horse serum to reduce proliferation. RNA was then purified from cells using Trizol reagent (Invitrogen) and 5 µg RNA was used for reverse transcription followed by PCR assays. The sequences of all specific primers used in PCR are available upon request.
Sumoylation assay in vitro. Recombinant proteins GST-SAE1/2, GSTUbc9, GST-SUMO-1-GG were produced in E. coli and purified using Pierce GST purification kit according to the protocol provided by the company. In a typical sumoylation assay, 300ng GST-SAE1/2, 500 ng GST-Ubc9, 500 ng GST-SUMO-1-GG were incubated with 2 µl Immunobiochemistry. Hela cells were seeded onto the glass coverslips and transfected with myc-tagged GATA4 wild type or its mutant K366R or wild type GATA4 in the presence of Ubc9 siRNA. 48 h after transfection, the cells were rinsed with 1XPBS and fixed in methanol for 30 min. After they were blocked in 5% nonfat milk overnight, these cells were probed with antibodies against myc and flag (Sigma) followed by Oregon Red or Green-labeled second antibody (Molecular Probe). DAPI was used to detect the location of nuclei.
Images were captured in an inverted fluorescent Zeiss microscopy (Germany).
Results
SUMO modification potentiated GATA4 activity. Additionally, as a negative control, GATA4 was also co-transfected with various amounts of SUMO-1-ΔGG expression vector (Fig.1C, lane 6,7,8 ), which differed from the wild type SUMO-1-GG by the removal of two C-terminal glycines, which are required for SUMO conjugation to its targets. As shown in Fig. 1C , a slower migrating band was readily observed in the presence of GATA4 and SUMO-1 by specific GATA4 antibody, moreover, the increase in SUMO-1 levels resulted in the increased intensity of the retarded band ( Lysine 366 in GATA4 is the major sumoylation site. The SUMOtargeted lysine lies within a canonical sequence ψKXE. The presence of one consensus sequence conserved in GATA4 was detected in five different vertebrate species (Fig. 2A) . Informatics guided our attention to lysine 366 localized in the C-terminal transactivation domain of GATA4. To determine if lysine 366 in GATA4 is the acceptor for SUMO-1, a single point mutant was generated at K366 (from K->R) in GATA4 and then tested in a sumoylation assay in vivo, by cotransfections with plasmid GATA and SUMO-1 expression vectors.
As shown in Fig. 2B , a sumoylated form of GATA4 was present on wild type GATA4 but not on K366R. Clearly, these data demonstrated that the major sumoylation site on GATA4 is the lysine residue 366.
We then asked if the mutated sumoylation site would affect the activation capacity of GATA4 mutant. As shown in Fig. 2C , only wild type GATA4 with SUMO-1 increased ANF promoter activation and K366R was unable to drive promoter activity, suggesting that the sumoylation site influenced GATA4 activity.
These data indicated that the function of GATA4 was enhanced via sumoylation on lysine residue 366 and was depressed by the mutation on that site.
Mutation on major sumoylation site of GATA4 did not affect its DNA binding activity but impacted its nucleo-cytoplasmic translocation. One of mechanisms by which SUMO regulates its target proteins' function is to alter the DNA binding activity (9, 44) . Due to the importance of DNA binding affinity for GATA4 transcriptional function, we asked if mutated SUMO target site would affect GATA4 DNA binding affinity. EMSA was conducted on the nuclear extract prepared from CV1 cells transfected with GATA4 wild type, or K366R. The oligo tested here is from Nkx2.5 enhancer containing one GATA binding site. The results show that mutant K366R exhibited the same DNA binding intensity as wild type GATA4 (Fig. 3A, upper panel) when they are equivalently expressed in the nucleus (Fig. 3A, lower panel) . GATA4 binding specificity was further confirmed by the application of GATA4 specific antibody.
Another mechanism whereby SUMO might alter its target function is to change its nuclear-cytoplasmic translocation (3). We asked if the mutated sumoylation sites would influence GATA4 nuclear localization, since GATA4 is usually localized to the nucleus. Immunofluorescent staining was performed on Hela cells transfected with myc-tagged GATA4 wt or K366R or wild type GATA4 together with Ubc9 siRNA (Fig. 3B) . Myc antibody was used to verify the GATA4 location and flag antibody for SUMO-1 localization. DAPI was applied to identify the nucleus. Around 15% cells among the GATA4-transfected cells showed diffused cytoplasmic and nuclear staining under our experimental conditions, however, mutation on K366 resulted in the increase of cytoplasmic staining up to 23%. To further investigate if sumoylation pathway contributes to GATA4 nuclear localization, Ubc9 siRNA, which specifically inhibited Ubc9 function in Hela cells(3), was cotransfected with wild type GATA4 into Hela cells. Inhibition of Ubc9 led to the increase in GATA4 diffusion to cytoplasm up to 33%, indicating that sumo-conjugation played a role in GATA4 nuclear translocation. These data suggest that GATA4 nuclear occupancy is at least partially attributable to the SUMO-modification of GATA4 on lysine 366.
PIAS1 regulated GATA4 sumoylation via its RING finger. E3 ligases,
such as the PIAS family, may substantially enhance the efficiency of sumoylation. In order to investigate the role of PIAS1 in GATA4 sumoylation in vivo, Hela cells were transfected with wild type GATA4 and SUMO-1 in presence or absence of PIAS1. As indicated in Fig. 4A lane 2 and 3 , intensified multisumoylated forms of GATA4 were observed that depend upon the presence of PIAS1. As a negative control, SUMO-1-ΔGG abolished the slower migrated GATA4-SUMO bands induced by the presence of PIAS1 (Fig. 4A, lane 5) ; thus, indicating that the two retarded bands were SUMO-1 conjugates. We then asked which domains in PIAS1 was responsible for potentiating GATA4 sumoylation reaction. The RING domain contains E3 ligase activity (28) , and the PIAS1 mutant in the RING finger (C345S/C350S/C355S) lead to the loss of intensified slower migrating bands as observed with wild type PIAS1 (Fig. 4A , compare lane two sumoylated forms of GATA4 by PIAS1, suggesting that lysine 366 is the primary SUMO target site located in GATA4 enhanced by PIAS1.
Since PIAS1 stimulated GATA4 sumoylation, did PIAS1 also affect GATA4 functional activity? GATA4, SUMO-1, or PIAS1 were transfected alone or in various combinations into CV1 cells together with the ANF promoter driving Luciferase reporter construct, as shown in Fig. 4C . PIAS1 alone hardly activated ANF promoter, and neither did SUMO-1. A modest synergy was observed between PIAS1 and GATA4 or GATA4 and SUMO-1 in stimulating the target promoter. However, the highest level of cooperative activation of the ANF promoter was observed among the co-transfectants, SUMO1, PIAS1 and GATA4 by ~35 fold. To further confirm that the RING domain of PIAS1 was critical to this combinatorial synergy among these 3 factors, we substituted wild type PIAS1 with the RING finger mutant exhibiting no E3 ligase activity in the transactivation assay, which reduced the synergy achieved by wild type PIAS1 from ~35 fold to less than 10 fold. Taken together, PIAS1 regulated GATA4 transcriptional activation capacity through enhancement of SUMO modification of GATA4 via its conserved RING finger domain. Taken together, these data suggest that SUMO modification was required for GATA4 to gain this ability to activate endogenous cardiac specified genes.
Discussion
SUMO modification provides a versatile regulatory mechanism whereby the functions of a wide range of proteins can be governed. Two GATA family members, GATA1 and 2, which are rich in hematopoietic cells, have been shown to be the substrates of SUMO modification that was enhanced by PIASy, although the physiological significance caused by this modification remains unknown (21, 41) . Our study demonstrated that another GATA family member, GATA4, which is plentiful in the heart, was also the target of SUMO-1. In contrast to GATA1 and 2 that are negatively regulated by SUMO and its E3 ligase, sumoylation modification positively modulated GATA4 transcriptional capacity.
Although the mutation on functional sumoylation site in GATA1 did not appear to have any significant effect on GATA1 function, our data suggests that the lysine 366 of GATA4 was a key site for sumoylation that is important to the regulation of GATA4 function.
PIAS family proteins were originally found to inhibit the functions of STATs via various mechanisms (45, 46) . It has been shown that this family may regulate activity of proteins via E3 ligase activity and/or protein-protein interaction. Our study provided evidence that PIAS1 significantly upregulated GATA4 dependent transactivation by enhancing the GATA4 sumoylation via its RING finger domain. We also noticed that RING domain mutant of PIAS1 still retained some synergy with GATA4 and SUMO-1 -albeit at a much lower level compared with that of wild type PIAS1; thus, suggestive of an alternative mechanism in regulating GATA4 function by PIAS1. Indeed, the physical interaction between GATA4 and PIAS1 is observed in co-immunoprecipitation assays although it is weak under our experimental conditions (data not shown).
Some studies previously showed that sumoylation and ubiquitination target the same lysine residues of some proteins, and that sumoylation competed against ubiquitination and consequently promoted the stability of targets (5, 6, 47) .
We observed that GATA4 was not ubiquitin-targeted (data not shown). Lin et al reported that SUMO-1 promotes nuclear accumulation of SMAD4 (3). Under normal conditions, GATA4 is exclusively located in the nucleus of cells where it exerts its roles in many cellular processes. Our findings indicate that mutation on SUMO-targeted lysine residue on 366 leads to reduced nuclear occupancy of GATA4 and greater appearance in the cytoplasm, although substantial amounts of mutant GATA4 was still seen in nucleus. This is one of the mechanisms whereby transcriptional activity of GATA4 was depressed by the lysine 366 mutation that did not obviously affect GATA4 DNA binding affinity.
It is also known that multiple molecules of ubiquitin may be linked to target proteins called the multi-ubiquitin chain (48) . In the process of SUMO modification, SUMO-2 and -3 have been shown to possess this ability to form polymeric chains on lysine residue 11 (49) , whereas the existence of this capacity for SUMO-1 has been debated (15, 26, 50) . For instance, there is no poly SUMO- We further examined whether GATA4 was able to turn on cardiac differentiation program in fibroblast 10T1/2 cells. With the assistance of SUMO-1 and/or PIAS1, GATA4 initiated the expression of cardiac α-myosin heavy chain and ANP, both of which are the targets of GATA4, but not cardiac α-actin (data not shown), suggesting that only a portion of the genetic readout required to induce a cardiac myocyte from a fibroblast was accomplished. Nevertheless, the mutation on lysine 366 of GATA4 abolished induction of the endogenous ANF and α-myosin heavy chain genes, indicating a role for SUMO in promoting cardiogenic gene activity. Given the fact that GATA4 is critically involved in heart development and considering that at least another cardiac enriched transcription factor, serum response factor, which is also indispensable for heart formation during embryogenesis (51) and forms mutual complexes involved with activation of SRF gene targets (52) was also recently shown to be a SUMO-1 target (53).
Thus, it is reasonable to postulate that SUMO and its E3 ligase might also foster GATA4-SRF interactions with other cardiogenic restricted co-factors such as the LIM-glycine rich proteins, CRP2 (42) and Nkx2-5 (54) that may further contribute to heart development. The reasonability of this hypothesis is further strengthened by the findings that PIAS proteins are involved in regulating BMP signal pathways that was also shown to have significant influence on cardiomyocyte differentiation (32, 55) . However, loss of function studies show that PIASy-/-mice did not exhibit any overt phenotype (29) , suggesting that redundancy of other PIAS family members might compensate for the lost of PIASy in vivo. In conclusion, the present study identified that GATA4 is a substrate of SUMO-1 that upregulated GATA4 transcriptional activation capacity via its attachment to lysine 366 on GATA4. PIAS1 strongly enhanced GATA4 sumoylation via its RING finger domain, which assisted in the initiation of cardiogenic gene activity in fibroblasts by GATA4. This study opens a new view into the potential roles of SUMO family and its E3 ligase in the heart development.
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